Request Demo
Emergent wins $235.8m US defence contract for Anthrax vaccine
VaccinePhase 3Drug ApprovalClinical Result
Emergent has several contracts with US government agencies for vaccines and therapeutics for various infectious diseases. Image Credit: Africa Studio / Shutterstock.
Emergentepartment of Defense (DoD) has awarded a procurement contract worth up to $235.8m to Emergentinfectious diseasesn indefinite-delivery and indefinite-quantity (IDIQ) supply of BioThrax.
As pUS Department of Defensergent will supply BioThrax to all US military members who have a Emergent BioSolutions to anthrax. The company will receive at least $20.1m for the initial five years ending on 30 September 2028. The contract allows for a five-year extension, with Emergent receiving at least $20m for each year, as per an 11 January press release.
Anthrax is an infectious disease caused by Bacillus anthracis, which occurs naturally in Food and Drug Administration (FDA) domestic and wild animals. Humans can contract anthrax if they come in contact with infected animals or contaminated animal products.
Anthraxt has several contracts with US government agencies for vaccines and therapeutics for various infectious diseases. In November 2023, the US Biomedical Advanced Reseanthraxd Development Authority (BARDA) awarded Emergent a $75m contract for the supply of its post-exposure prophylactic anthrax vaccine, Cyfendus.
Emergent2023, Emergent signed a ten-year contract with BARDA for the advanced development, manufacturinfectious diseasesrocurement of Ebanga (ansuvBiomedical Advanced Research and Development Authority (BARDA)Ebola virEmergentse by the FDA in 2020. The ten-year BARDA contract is divided into two option perioCyfendus advanced development option valued at $121m, and the procurement option valued at $583m over five years.
In May 2023, EEmergentsold its travel vaccine portfolioBARDAch included marketed vaccines for typhoid fever and cholera, and the PhaseEbangahiansuvimab-zyklne candidate to Bavarian Nordic. In August 2023, BavaEbola virus diseaseive toplFDA data from the Phase IIBARDAdy of its virus-like particle (VLP)-based chikungunya virus vaccine CHIKV VLP (PXVX0317) in adults and adolescents. The vaccine induced neutralising antibodies in 98% of the participants in the active group.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.